NO319497B1 - Ekspresjonssystem for fremstilling av apolipoprotein AI-M - Google Patents

Ekspresjonssystem for fremstilling av apolipoprotein AI-M Download PDF

Info

Publication number
NO319497B1
NO319497B1 NO19952297A NO952297A NO319497B1 NO 319497 B1 NO319497 B1 NO 319497B1 NO 19952297 A NO19952297 A NO 19952297A NO 952297 A NO952297 A NO 952297A NO 319497 B1 NO319497 B1 NO 319497B1
Authority
NO
Norway
Prior art keywords
apo
apolipoprotein
cultivation
approx
medium
Prior art date
Application number
NO19952297A
Other languages
English (en)
Norwegian (no)
Other versions
NO952297D0 (no
NO952297L (no
Inventor
Erik Holmgren
Mats Lake
Lars Abrahmsen
Christina Kalderen
Ase Mikaelsson
Torsten Sejlitz
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of NO952297D0 publication Critical patent/NO952297D0/no
Publication of NO952297L publication Critical patent/NO952297L/no
Publication of NO319497B1 publication Critical patent/NO319497B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19952297A 1992-12-11 1995-06-09 Ekspresjonssystem for fremstilling av apolipoprotein AI-M NO319497B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9203753A SE9203753D0 (sv) 1992-12-11 1992-12-11 Expression system for producing apolipoprotein ai-m
PCT/SE1993/001061 WO1994013819A1 (en) 1992-12-11 1993-12-09 Expression system for producing apolipoprotein ai-m

Publications (3)

Publication Number Publication Date
NO952297D0 NO952297D0 (no) 1995-06-09
NO952297L NO952297L (no) 1995-06-09
NO319497B1 true NO319497B1 (no) 2005-08-22

Family

ID=20388112

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19952297A NO319497B1 (no) 1992-12-11 1995-06-09 Ekspresjonssystem for fremstilling av apolipoprotein AI-M

Country Status (22)

Country Link
US (1) US5721114A (pl)
EP (1) EP0677109B1 (pl)
JP (1) JP3899121B2 (pl)
AT (1) ATE191930T1 (pl)
AU (1) AU5663794A (pl)
CA (1) CA2150928C (pl)
CZ (1) CZ290865B6 (pl)
DE (1) DE69328442T2 (pl)
DK (1) DK0677109T3 (pl)
ES (1) ES2146646T3 (pl)
FI (1) FI952847A0 (pl)
GR (1) GR3033966T3 (pl)
HU (1) HU220193B (pl)
IL (1) IL107896A (pl)
MX (1) MX9307855A (pl)
NO (1) NO319497B1 (pl)
PL (1) PL175955B1 (pl)
PT (1) PT677109E (pl)
SE (1) SE9203753D0 (pl)
SK (1) SK76695A3 (pl)
WO (1) WO1994013819A1 (pl)
ZA (1) ZA939266B (pl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
AU728257B2 (en) * 1995-11-09 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The The use of lecithin-cholesterol acyltransferase (LCAT) in the treatment of atherosclerosis
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
CN1297932A (zh) * 1999-11-30 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
EP2343317A1 (en) * 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
AU2002362612B2 (en) * 2001-09-28 2007-11-15 Cedars-Sinai Medical Center Prevention and treatment of restenosis by local administration of drug
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
JP2005511713A (ja) * 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
BR0310100A (pt) * 2002-05-17 2007-04-27 Esperion Therapeutics Inc métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
AU2003239489A1 (en) 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
HUE036646T2 (hu) 2003-01-23 2018-07-30 Esperion Therapeutics Inc Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra
EP1602720B1 (en) * 2003-03-05 2010-11-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for producing heterologous protein in e. coli
WO2005058938A2 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
JP2007531537A (ja) * 2004-04-06 2007-11-08 セダーズ−シナイ　メディカル　センター アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
CN1320119C (zh) * 2004-12-09 2007-06-06 复旦大学 人载脂蛋白ApoAⅠ在毕赤氏酵母胞内表达的方法
JP5113752B2 (ja) 2005-08-22 2013-01-09 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤
AU2006282722A1 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics Holdings S.A. Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
DE102006004871A1 (de) 2006-02-02 2007-08-09 Wacker Chemie Ag Mikroorganismenstamm zur Produktion von rekombinanten Proteinen
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
CA2653840A1 (en) 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Use of a peptide/phospholipid complex acting as a reverse lipid transport agonist for treatment of valvular stenosis
ATE501266T1 (de) 2006-09-22 2011-03-15 Wacker Chemie Ag Verfahren zur fermentativen herstellung von antikörpern
DE102006044841A1 (de) 2006-09-22 2008-04-03 Wacker Chemie Ag Signalpeptid zur Produktion von rekombinanten Proteinen
DE102006050332A1 (de) 2006-10-25 2008-04-30 Wacker Chemie Ag DNS-Konstrukt und Verfahren zur fermentativen Herstellung von Fusionsproteinen
CA3021932C (en) * 2007-01-31 2020-12-15 Jds Therapeutics, Llc Use of chromium histidinate for treatment of cardiometabolic disorders
CA2678813A1 (en) * 2007-02-20 2008-08-28 Melior Pharmaceuticals I, Inc. Methods of identifying activators of lyn kinase
ES2841379T3 (es) 2007-03-13 2021-07-08 Jds Therapeutics Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
CA2693809A1 (en) * 2007-07-23 2009-01-29 Melior Discovery, Inc. Methods of activating irs-1 and akt
EA201070517A1 (ru) * 2007-10-23 2010-12-30 Дзе Кливленд Клиник Фаундейшн Устойчивый к окислителям аполипопротеин а-1 и пептиды-миметики
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
HUE037082T2 (hu) 2008-11-10 2018-08-28 Arbutus Biopharma Corp Új lipidek és készítmények terápiás hatóanyagok szállítására
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
LT2939683T (lt) 2009-02-16 2017-03-27 Cerenis Therapeutics Holding Sa Apolipoproteino a-i mimetikai
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
KR20180094137A (ko) 2009-05-05 2018-08-22 알닐람 파마슈티칼스 인코포레이티드 지질 조성물
MX342785B (es) 2009-06-10 2016-10-12 Alnylam Pharmaceuticals Inc Formulacion mejorada de lipido.
US9029338B2 (en) 2009-08-14 2015-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
DE102009053566B4 (de) * 2009-11-11 2014-08-14 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Mikroorganismen mit gesteigerter Sucrosemutaseaktivität
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
CA2784568A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Lipid particles for delivery of nucleic acids
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
SG186085A1 (en) 2010-06-03 2013-01-30 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
BR112013004396A2 (pt) * 2010-08-30 2016-05-17 Hoffmann La Roche alimentação alcalina
US9339513B2 (en) 2010-11-09 2016-05-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
EP2673296B1 (en) 2011-02-07 2018-10-24 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and uses thereof
AU2012223282B2 (en) 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
EP2760477B1 (en) 2011-09-27 2018-08-08 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
EP2790704B1 (en) 2011-12-12 2019-04-03 Melior Pharmaceuticals I, Inc. Treatment of type i diabetes
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
WO2015173633A2 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
CA3014308A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
US10426817B2 (en) * 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
SG11201909406VA (en) 2017-04-10 2019-11-28 Melior Pharmaceuticals I Inc Treatment of adipocytes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
DE68917379T2 (de) * 1988-05-31 1994-12-01 Mitsubishi Chem Ind Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind.
DE3819463A1 (de) * 1988-06-08 1989-12-14 Behringwerke Ag Expressionsvektoren zur herstellung unfusionierter proteine in mikroorganismen
US5223407A (en) * 1988-08-31 1993-06-29 Allelix Inc. Excretion of heterologous proteins from e. coli
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
HU214828B (hu) * 1989-10-31 1998-06-29 Schering Corp. Eljárás heterológ proteinek táptalajba való kiválasztására képes E. coli törzsek előállítására és heterológ proteinek termelésére
DE4009268A1 (de) * 1990-03-22 1991-09-26 Consortium Elektrochem Ind Sekretion von hirudinderivaten
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein

Also Published As

Publication number Publication date
GR3033966T3 (en) 2000-11-30
HU220193B (hu) 2001-11-28
DE69328442T2 (de) 2000-09-07
PL175955B1 (pl) 1999-03-31
US5721114A (en) 1998-02-24
EP0677109B1 (en) 2000-04-19
IL107896A (en) 2004-06-01
PT677109E (pt) 2000-07-31
AU5663794A (en) 1994-07-04
ZA939266B (en) 1994-08-08
PL309292A1 (en) 1995-10-02
JP3899121B2 (ja) 2007-03-28
ATE191930T1 (de) 2000-05-15
CA2150928C (en) 2005-02-08
CA2150928A1 (en) 1994-06-23
SE9203753D0 (sv) 1992-12-11
FI952847L (fi) 1995-06-09
DE69328442D1 (de) 2000-05-25
FI952847A7 (fi) 1995-06-09
FI952847A0 (fi) 1995-06-09
JPH08506723A (ja) 1996-07-23
HUT71697A (en) 1996-01-29
HU9501680D0 (en) 1995-08-28
CZ148795A3 (en) 1996-01-17
EP0677109A1 (en) 1995-10-18
NO952297D0 (no) 1995-06-09
IL107896A0 (en) 1994-04-12
MX9307855A (es) 1994-06-30
SK76695A3 (en) 1996-02-07
DK0677109T3 (da) 2000-07-17
CZ290865B6 (cs) 2002-11-13
NO952297L (no) 1995-06-09
WO1994013819A1 (en) 1994-06-23
ES2146646T3 (es) 2000-08-16

Similar Documents

Publication Publication Date Title
NO319497B1 (no) Ekspresjonssystem for fremstilling av apolipoprotein AI-M
KR100316347B1 (ko) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
US5357044A (en) Cecropins fusion proteins
US5206154A (en) Method of producing cecropins by microbiological techniques
JP4857279B2 (ja) カルボキシ末端をアミド化したペプチドの製造方法
EP0460709B1 (en) AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
Ritz et al. The cycHJKL gene cluster plays an essential role in the biogenesis of c-type cytochromes in Bradyrhizobium japonicum
CA2896157A1 (en) Methods and compositions relating to crm197
JP5352234B2 (ja) 特定のエンドプロテアーゼによって塩基性アミノ酸のｃ末端を用いてポリペプチドをアミド化する方法
KR20230062618A (ko) 합성 발현 시스템
RU2144957C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pPINS07, КОДИРУЮЩАЯ ГИБРИДНЫЙ ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ПРОИНСУЛИН ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ ГИБРИДНОГО ПОЛИПЕПТИДА, СОДЕРЖАЩЕГО ПРОИНСУЛИН ЧЕЛОВЕКА
JP2019195327A (ja) 枯草菌（ｂａｃｉｌｌｕｓ ｓｕｂｔｉｌｉｓ）において真正で生物活性を有する塩基性線維芽細胞増殖因子を発現させる方法及び手段
CN114181321B (zh) 花鲈fgf6a、fgf6b以及fgf18重组蛋白及其制备方法和应用
KR100242268B1 (ko) 화학 화합물의 생합성적 제조방법
JP2007501622A (ja) 組換えポリペプチドを精製するための方法
EP0046669A1 (en) Somatostatin or somatostatin precursors
WO2014097323A1 (en) Novel fusion tags and expression vector system for the expression of human parathyroid hormone (rhpth)
WO1986003779A1 (fr) Vecteur de secretion de polypeptides, micro-organismes transformes par ledit vecteur, et procede de preparation de polypeptides avec lesdits micro-organismes
MX2014010082A (es) Metodo para la reduccion de desplazamientos del marco de lectura 1->2.
Chuang et al. A dual-functional E. coli vector for expressing recombinant protein with high solubility and antigen presentation ability
Price et al. Cloning and sequence analysis of the gene encoding Methylophilus methylotrophus cytochrome c ″, a unique protein with a perpendicular orientation of the histidinyl ligands
JP2000078989A (ja) ヒト成長ホルモンの分泌生産方法
KR20040007892A (ko) 재조합 인간 훼리틴 단백질 및 그 제조방법
Locht et al. N-terminal characterization of the Bordetella pertussis filamentous hemagglutinin
JPH0723788A (ja) 神経栄養因子の生産方法及びそのためのべクター